Key Takeaways Bayer (BAYRY) announced that it has won approval for pipeline drug elinzanetant in the UK for the treatment of moderate to severe vasomotor symptoms (VMS or hot flashes) associated with menopause. The Medicines and Healthcare products Regulatory Agency, a regulatory authority in the UK, has authorized the use of elinzanetant, under the brand name Lynkuet for the above-mentioned indication. Year to date, shares of Bayer have rallied 67% compared to the industry's gain of 2.7%. Bayer's new produ ...